SMC Global Securities
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceuticals ingredients. The company continues to invest in enhancing specialty and complex generic pipeline for a sustainable growth. A diversified portfolio with limited product concentration risk is expected to help the company deal with price erosion challenges in the US.
All the key market continues to do well and has shown a healthy growth trend. It is expected that the stock will see a target price of Rs 792 in 8-10 months timeframe on a one-year average P/E of 16.77x and FY19 (E) earnings of Rs 47.20.
Disclaimer: The views and investment tips expressed on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
